雅虎香港 搜尋

搜尋結果

1. booking.health.gov.tw臺北市政府衛生局COVID-19疫苗接種地點資訊查詢

   booking.health.gov.tw

   • 網頁紀錄

   3 天前 · 臺北市政府衛生局COVID-19疫苗接種地點資訊查詢. 一、臺北市自113年10月1日起，提供莫德納JN.1疫苗，分兩階段接種：(一)第一階段(113/10/1-113/10/31)：1.醫事及衛生防疫相關人員2.65歲以上者3.55歲以上原住民4.安養、長期照顧(服務)等機構之受照顧者及其所屬工作人員5 ...

2. www.chp.gov.hk › en › featuresStatistics on Government COVID-19 Vaccination Programme

   www.chp.gov.hk › en › features

   • 網頁紀錄

   4 天前 · Administration of Comirnaty (BioNTech) vaccine started on 10 March 2021 (Remark: suspended from 24 March to 4 April) . A number of individuals received doses of the CoronaVac (Sinovac) and Comirnaty (BioNTech) vaccines during the soft launch of the COVID-19 Vaccination Programme (before official launch).

3. 其他人也問了

   Does biontech have a clinical hold on bnt316/onc-392?

   • BioNTech (NASDAQ: BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug candidate BNT316/ONC-392 in the treatment of non-small cell lung cancer, or NSCLC. In an SEC filing, BioNTech said the hold was placed due to “varying results between the squamous and non-squamous NSCLC patient populations.”

   BioNTech, OncoC4 Phase 3 study put on partial hold by FDA

   seekingalpha.com/news/4175259-biontech-oncoc4-phase-3-study-put-on-partial-hold-by-fda

   查看此問題的所有搜尋結果

   Why did biontech stock fall Friday?

   • Investing.com -- BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed partial clinical hold on Phase 3 study of BNT316/ONC-392 (gotistobart) in non-small cell lung cancer.

   BioNTech shares slip as FDA places partial clinical hold on lung cancer s…

   finance.yahoo.com/news/biontech-shares-slip-fda-places-142544359.html

   查看此問題的所有搜尋結果

   Will biontech & oncoc4 co-develop bnt316/onc-392?

   • BioNTech and OncoC4 entered into an agreement to co-develop ONC-392 in March 2023. BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the treatment of non-small cell lung cancer.

   BioNTech, OncoC4 Phase 3 study put on partial hold by FDA

   seekingalpha.com/news/4175259-biontech-oncoc4-phase-3-study-put-on-partial-hold-by-fda

   查看此問題的所有搜尋結果

   Will patients enrolled in biontech study continue to receive treatment?

   • BioNTech said patients already enrolled in the study will continue to receive treatment while the companies assess the next steps. Studies for the drug candidate in other indications are unaffected by the hold.

   BioNTech, OncoC4 Phase 3 study put on partial hold by FDA

   seekingalpha.com/news/4175259-biontech-oncoc4-phase-3-study-put-on-partial-hold-by-fda

   查看此問題的所有搜尋結果

   What happened to oncoc4 and biontech?

   • Following this discovery, OncoC4 and BioNTech have voluntarily paused the enrollment of new patients into the trial and have reported the observed variances to the FDA for further review and guidance. Despite the partial clinical hold, patients who are already participating in the trial will continue to receive their treatment as planned.

   BioNTech shares slip as FDA places partial clinical hold on lung cancer s…

   finance.yahoo.com/news/biontech-shares-slip-fda-places-142544359.html

   查看此問題的所有搜尋結果

   Who owns biontech?

   • Şahin, who was born in Turkey and grew up in Germany, owns about 17% of BioNTech, which went public on the Nasdaq in October 2019. In 2001 Şahin and his immunologist wife, ?zlem T'reci, cofounded Ganymed Pharmaceuticals; Astellas Pharma acquired Ganymed in 2016 for $460 million.

   Ugur Sahin - Forbes

   www.forbes.com/profile/ugur-sahin/

   查看此問題的所有搜尋結果

4. investors.biontech.de › static-files › d06220f0/4525/4d3c-9495Form 6-K for Biontech SE filed 10/18/2024

   investors.biontech.de › static-files › d06220f0/4525/4d3c-9495

   23 小時前 · INFORMATION INCLUDED AS PART OF THIS FORM 6-K. BioNTech SE (“BioNTech”) has been informed by its partner OncoC4, Inc. (“OncoC4”) that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the companies’ two-stage, open-label, randomized Phase 3 trial, PRESERVE-003 (NCT05671510). BioNTech and OncoC4 ...

5. www.fiercebiotech.com › biotech › biontech-oncoc4-phase-3-putFDA puts partial hold on BioNTech-OncoC4 phase 3 trial

   www.fiercebiotech.com › biotech › biontech-oncoc4-phase-3-put

   23 小時前 · BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported. Patients already enrolled in the late-stage cancer trial will continue to receive treatment. (LinkedIn) The ...

6. seekingalpha.com › news › 4175259-biontech-oncoc4-phase-3BioNTech, OncoC4 Phase 3 study put on partial hold by FDA

   seekingalpha.com › news › 4175259-biontech-oncoc4-phase-3

   9 小時前 · BioNTech (NASDAQ: BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug candidate BNT316/ONC-392 in the treatment of non-small cell lung cancer, or ...

7. finance.yahoo.com › news › biontech-shares-slip-fda-placesBioNTech shares slip as FDA places partial clinical hold on ...

   finance.yahoo.com › news › biontech-shares-slip-fda-places

   • 網頁紀錄

   9 小時前 · PFE. Investing.com -- BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed partial clinical hold on Phase 3 study of BNT316/ONC ...

8. www.forbes.com › profile › ugur-sahinUgur Sahin - Forbes

   www.forbes.com › profile › ugur-sahin

   • 網頁紀錄

   3 天前 · Uğur Şahin is CEO and cofounder of German biotech firm BioNTech, which partnered with Pfizer to produce the first Covid-19 vaccine approved in the US.